The Patient Journey in Prostate Cancer: Key Points for Nurses

  • Christine RemacleEmail author
Part of the Principles of Specialty Nursing book series (PSN)


The optimal care pathway for patients with prostate cancer (PCa) should be multidisciplinary and multi-professional. Nurses from a variety of disciplines (e.g. medical oncology, urology, radiation oncology) should be implicated in educating patients and guiding patient care across the broad spectrum of available treatments.

For this purpose, nurses involved in managing PCa patients should be educated about the different treatments and their possible adverse events. Most PCa are slow-growing indolent tumours that will be best managed by active surveillance. Nurses play an important role in reassuring and empowering the patient in that process. Localised disease is best treated by surgery and/or radiotherapy, each offering a different philosophical approach. Nurses play a central role in guiding the patient in the difficult decision of the treatment choice. They will be the guardian of a shared decision-making and protect the principle of equipoise by involving patients in the treatment choices. Advanced PCa, at its various stages of progression, is most often treated by hormonal therapy. Hormone therapy does not eradicate PCa but rather switches it to a more chronic state. This means that the patients will be treated for an extended period of time. Hormone therapy may profoundly affect various emotional and physical aspects of the patients and severely impacts its well-being. Countermeasures are known but rarely explained to patients. Nurses are ideally positioned to provide treatment information, education and self-management recommendations regarding side effects and symptom management. According to these numerous treatments, all nurses will be there to provide emotional and psychological support regarding patient’s coping process which will improve adherence in his treatment plan.


Prostate cancer Prevention Risk factor Treatments Side effects Education Adherence 


  1. 1.
    Global Burden of Disease Cancer C, Fitzmaurice C, Allen C, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524–48.CrossRefGoogle Scholar
  2. 2.
    Cuzick J, Thorat MA, Andriole G, et al. Prevention and early detection of prostate cancer. Lancet Oncol. 2014;15(11):e484–92.PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Butoescu V, Ambroise J, Stainier A, Dekairelle AF, Gala JL, Tombal B. Does genotyping of risk-associated single nucleotide polymorphisms improve patient selection for prostate biopsy when combined with a prostate cancer risk calculator? Prostate. 2014;74(4):365–71.PubMedCrossRefGoogle Scholar
  4. 4.
    Gillessen S, Attard G, Beer TM, et al. Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017. Eur Urol. 2015;67(5):825–36.Google Scholar
  5. 5.
    Paner GP, Stadler WM, Hansel DE, Montironi R, Lin DW, Amin MB. Updates in the eighth edition of the tumor-node-metastasis staging classification for urologic cancers. Eur Urol. 2018;73(4):560–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Sartor O, Eisenberger M, Kattan MW, Tombal B, Lecouvet F. Unmet needs in the prediction and detection of metastases in prostate cancer. Oncologist. 2013;18(5):549–57.PubMedPubMedCentralCrossRefGoogle Scholar
  7. 7.
    Epstein JI, Amin MB, Reuter VE, Humphrey PA. Contemporary Gleason grading of prostatic carcinoma: an update with discussion on practical issues to implement the 2014 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. Am J Surg Pathol. 2017;41(4):e1–7.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618–29.PubMedCrossRefGoogle Scholar
  9. 9.
    Droz JP, Aapro M, Balducci L, et al. Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncol. 2014;15(9):e404–14.PubMedCrossRefGoogle Scholar
  10. 10.
    Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol. 2011;29(10):1335–41.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Parmelee PA, Thuras PD, Katz IR, Lawton MP. Validation of the cumulative illness rating scale in a geriatric residential population. J Am Geriatr Soc. 1995;43(2):130–7.PubMedCrossRefGoogle Scholar
  12. 12.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–83.CrossRefGoogle Scholar
  13. 13.
    Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate Cancer. N Engl J Med. 2016;375(15):1415–24.PubMedCrossRefGoogle Scholar
  14. 14.
    Wilt TJ, Jones KM, Barry MJ, et al. Follow-up of prostatectomy versus observation for early prostate Cancer. N Engl J Med. 2017;377(2):132–42.PubMedCrossRefGoogle Scholar
  15. 15.
    Ahmed HU, Bosaily AE, Brown LC, et al. The PROMIS study: a paired-cohort, blinded confirmatory study evaluating the accuracy of multi-parametric MRI and TRUS biopsy in men with an elevated PSA. J Clin Oncol. 2016;34(suppl):a5000.CrossRefGoogle Scholar
  16. 16.
    Donovan JL, Hamdy FC, Lane JA, et al. Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer. N Engl J Med. 2016;375(15):1425–37.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Barocas DA, Alvarez J, Resnick MJ, et al. Association between radiation therapy, surgery, or observation for localized prostate cancer and patient-reported outcomes after 3 years. JAMA. 2017;317(11):1126–40.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Ost P, Reynders D, Decaestecker K, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5):446–53.PubMedCrossRefGoogle Scholar
  19. 19.
    Tyson MD 2nd, Koyama T, Lee D, et al. Effect of prostate cancer severity on functional outcomes after localized treatment: comparative effectiveness analysis of surgery and radiation study results. Eur Urol. 2018;74(1):26–33.PubMedCrossRefGoogle Scholar
  20. 20.
    Vale CL, Fisher DJ, White IR, et al. What is the optimal systemic treatment of men with metastatic, hormone-naive prostate cancer? A STOPCAP systematic review and network meta-analysis. Ann Oncol. 2018;29(5):1249–57.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Millar RP, Lu ZL, Pawson AJ, Flanagan CA, Morgan K, Maudsley SR. Gonadotropin-releasing hormone receptors. Endocr Rev. 2004;25(2):235–75.PubMedCrossRefGoogle Scholar
  22. 22.
    Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Klotz L, Miller K, Crawford ED, et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol. 2014;66(6):1101–8.PubMedCrossRefGoogle Scholar
  24. 24.
    Bourke L, Smith D, Steed L, et al. Exercise for men with prostate cancer: a systematic review and meta-analysis. Eur Urol. 2016;69(4):693–703.PubMedCrossRefGoogle Scholar
  25. 25.
    Lebret T, Coloby P, Descotes JL, Droupy S, Geraud M, Tombal B. Educational tool-kit on diet and exercise: survey of prostate cancer patients about to receive androgen deprivation therapy. Urology. 2010;76(6):1434–9.PubMedCrossRefGoogle Scholar
  26. 26.
    Tombal B. A holistic approach to androgen deprivation therapy: treating the cancer without hurting the patient. Urol Int. 2009;83(4):373–8.PubMedCrossRefGoogle Scholar
  27. 27.
    Aucoin MW, Wassersug RJ. The sexuality and social performance of androgen-deprived (castrated) men throughout history: implications for modern day cancer patients. Soc Sci Med. 2006;63(12):3162–73.PubMedCrossRefGoogle Scholar
  28. 28.
    Moyad MA. Promoting general health during androgen deprivation therapy (ADT): a rapid 10-step review for your patients. Urol Oncol. 2005;23(1):56–64.PubMedCrossRefGoogle Scholar
  29. 29.
    Strum SB, McDermed JE, Scholz MC, Johnson H, Tisman G. Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. Br J Urol. 1997;79(6):933–41.PubMedCrossRefGoogle Scholar
  30. 30.
    Pezaro C, Mukherji D, Tunariu N, et al. Sarcopenia and change in body composition following maximal androgen suppression with abiraterone in men with castration-resistant prostate cancer. Br J Cancer. 2013;109(2):325–31.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Nanda A, Chen MH, Braccioforte MH, Moran BJ, D’Amico AV. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. JAMA. 2009;302(8):866–73.PubMedCrossRefGoogle Scholar
  32. 32.
    Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65(3):565–73.PubMedCrossRefGoogle Scholar
  33. 33.
    Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab. 2006;91(4):1305–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Keating NL, O’Malley AJ, Freedland SJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010;102(1):39–46.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Galvao DA, Nosaka K, Taaffe DR, et al. Resistance training and reduction of treatment side effects in prostate cancer patients. Med Sci Sports Exerc. 2006;38(12):2045–52.PubMedCrossRefGoogle Scholar
  36. 36.
    Eriksson S, Eriksson A, Stege R, Carlstrom K. Bone mineral density in patients with prostate cancer treated with orchiectomy and with estrogens. Calcif Tissue Int. 1995;57(2):97–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Alibhai SM, Duong-Hua M, Cheung AM, et al. Fracture types and risk factors in men with prostate Cancer on androgen deprivation therapy: a matched cohort study of 19,079 men. J Urol. 2010;184(3):918–23.PubMedCrossRefGoogle Scholar
  38. 38.
    Nguyen PL, Alibhai SM, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015;67(5):825–36.PubMedCrossRefGoogle Scholar
  39. 39.
    Benton MJ, White A. Osteoporosis: recommendations for resistance exercise and supplementation with calcium and vitamin D to promote bone health. J Community Health Nurs. 2006;23(4):201–11.PubMedCrossRefGoogle Scholar
  40. 40.
    Network NCC. Prostate cancer. 2017. Accessed 21 Feb 2017, 2015.
  41. 41.
    Butoescu V, Tombal B. Practical guide to bone health in the spectrum of advanced prostate cancer. Can J Urol. 2014;21(2 Suppl 1):84–92.PubMedGoogle Scholar
  42. 42.
    Attard G, Reid AH, Yap TA, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008;26(28):4563–71.PubMedCrossRefGoogle Scholar
  43. 43.
    Fizazi K, Tran N, Fein L, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377(4):352–60.PubMedCrossRefGoogle Scholar
  44. 44.
    James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338–51.PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2015;16(2):152–60.PubMedCrossRefGoogle Scholar
  46. 46.
    Agency EM. Summary of the European public assessment report (EPAR) for Zytiga. 2018. Accessed 30 Apr 2018.
  47. 47.
    Tombal B. Non-metastatic CRPC and asymptomatic metastatic CRPC: which treatment for which patient? Ann Oncol Off J Eur Soc Med Oncol/ESMO. 2012;23(Suppl 10):x251–8.CrossRefGoogle Scholar
  48. 48.
    Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study. Lancet. 2010;375(9724):1437–46.PubMedPubMedCentralCrossRefGoogle Scholar
  49. 49.
    Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.CrossRefGoogle Scholar
  51. 51.
    Chowdhury S, Shore N, Saad F, et al. Fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide: data from randomised clinical trials. Ann Oncol. 2016;27 (suppl_6):739P.Google Scholar
  52. 52.
    Agency EM. Summary of the European public assessment report (EPAR) for Xtandi. 2015. Accessed 30 Apr 2018, 2017.
  53. 53.
    Horne R, Weinman J. Patients’ beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6):555–67.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.King Albert II Institute for Cancerology and HaematologyCliniques Universitaires Saint-LucBrusselsBelgium

Personalised recommendations